MannKind CEO Michael Castagna (file photo) Westlake Village-based MannKind Corporation saw shares climb 8% on Jan. 2 after the company announced entering into a royalty purchase agreement of up to $200 million. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary arterial hypertension, sold a 1% royalty in net sales of Tyvaso DPI